Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 7, 2015; 21(37): 10688-10696
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10688
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10688
Age (yr) | |
median | 63 |
range | 32-84 |
Gender | |
Male | 3 (7.3) |
Female | 38 (92.7) |
Tumor stage | |
T1 | 3 (7.3) |
T2 | 19 (46.3) |
T3 | 10 (24.4) |
T4 | 9 (22) |
Nodal stage | |
N0 | 16 (39) |
N1 | 18 (44) |
N2 | 6 (14.6) |
N3 | 1 (2.4) |
Staging | |
I | 2 (4.8) |
II | 13 (31.8) |
IIIA | 12 (29.3) |
IIIB | 14 (34.1) |
Smoke | |
Yes | 18 (44) |
No | 7 (17) |
Unknown | 16 (39) |
Histology | |
SCC | 41 (100) |
Chemotherapy | |
MMC + 5-FU | 33 (80.7) |
MMC + Capecitabine | 4 (9.7) |
Capecitabine | 2 (4.8) |
None | 2 (4.8) |
- Citation: Belgioia L, Vagge S, Agnese D, Garelli S, Murialdo R, Fornarini G, Chiara S, Gallo F, Bacigalupo A, Corvò R. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. World J Gastroenterol 2015; 21(37): 10688-10696
- URL: https://www.wjgnet.com/1007-9327/full/v21/i37/10688.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i37.10688